Analysed MOLECULIN BIOTECH INC (MBRX:NASDAQ) News Sources
Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout
23-03-2026
yahoo.com
Moleculin Releases Next CEO Corner Segment Highlighting Annamycin’s Non-Cardiotoxic Profile
07-04-2026
yahoo.com
Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting
21-04-2026
yahoo.com
Moleculin’s Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026
23-04-2026
yahoo.com
Moleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin
08-05-2026
yahoo.com
Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits
12-05-2026
yahoo.com
Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks
13-05-2026
yahoo.com
Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial
15-05-2026
yahoo.com
What is the current price of MOLECULIN BIOTECH INC (MBRX:NASDAQ)?
The current price of MOLECULIN BIOTECH INC (MBRX:NASDAQ) is $2.73.
MOLECULIN BIOTECH INC (MBRX:NASDAQ) absolute price change since previous trading day?
The absolute price change of MOLECULIN BIOTECH INC (MBRX:NASDAQ) since the previous trading day is $0.28.
MOLECULIN BIOTECH INC (MBRX:NASDAQ) percentage price change since previous trading day?
The percentage price change of MOLECULIN BIOTECH INC (MBRX:NASDAQ) since the previous trading day is 11.4286%.
What is the most recent average sentiment score for MOLECULIN BIOTECH INC (MBRX:NASDAQ)?
The most recent average sentiment score for MOLECULIN BIOTECH INC (MBRX:NASDAQ) is 66 out of 100.
What is the most recent average sentiment for MOLECULIN BIOTECH INC (MBRX:NASDAQ)?
The most recent sentiment for MOLECULIN BIOTECH INC (MBRX:NASDAQ) is .
SEC-8K** Filing Available For MOLECULIN BIOTECH INC (MBRX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.